Evidence map›Paper›PMID 32518984›Full record

ArticleEuropean radiology2020

Hemosiderin deposition in papillary renal cell carcinoma and its potential to mask enhancement on MRI: analysis of 110 cases.

Hiroaki Takahashi, Akira Kawashima, Akitoshi Inoue, Kazuto Kozaka, Theodora A Potretzke, Adam T Froemming, Stephen A Boorjian, Mitchell R Humphreys, Naoki Takahashi

Abstract read
PubMed Publisher
In one paragraph

Article in European radiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Hiroaki TakahashiDepartment of Diagnostic Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Akira KawashimaDepartment of Diagnostic Radiology, Mayo Clinic, Phoenix, AZ, USA.
Akitoshi InoueDepartment of Diagnostic Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Kazuto KozakaDepartment of Diagnostic Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Theodora A PotretzkeDepartment of Diagnostic Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Adam T FroemmingDepartment of Diagnostic Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA.
Stephen A BoorjianDepartment of Urology, Mayo Clinic, Rochester, MN, USA.
Mitchell R HumphreysDepartment of Urology, Mayo Clinic, Phoenix, AZ, USA.
Naoki TakahashiDepartment of Diagnostic Radiology, Mayo Clinic, 200 First St. SW, Rochester, MN, 55905, USA. Takahashi.Naoki@mayo.edu.
Mayo Clinic · USMayo Clinic Hospital · USMayo Clinic in Arizona · USWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo evaluate the relationship between imperceptible T1 enhancement of papillary renal cell carcinoma (pRCC) on MR and intratumoral hemosiderin deposition.

methodsOne hundred ten pRCCs (≤ 7 cm) were evaluated by MR with in- and opposed-phase spoiled gradient echo (GRE) and T1-weighted spoiled GRE with fat suppression before and after contrast. Hemosiderin deposition was assessed by SI

resultsFive (5%), 10 (9%), and 95 (86%) tumors were categorized as grades 1, 2, and 3 enhancement, respectively. The mean SI

conclusionspRCC with no subjective enhancement on contrast-enhanced MR showed hemosiderin deposition evident by lower SI KEY POINTS: • 5% of papillary renal cell carcinoma showed imperceptible enhancement on contrast-enhanced MR. • Hemosiderin deposition in papillary renal cell carcinoma might mask the tumor enhancement on contrast-enhanced MR due to T2/T2*-shortening effects. • A renal lesion with extensive hemosiderin deposition but no perceptible enhancement on MR should be considered suspicious for papillary renal cell carcinoma.

Indexed as

AdultAgedAged, 80 and overCarcinoma, Renal CellContrast MediaFemaleHemosiderinHumansKidneyKidney NeoplasmsMagnetic Resonance ImagingMaleMiddle AgedYoung AdultContrast MediaHemosiderinChemical shift imagingsContrast agentHemosiderinMagnetic resonance imagingPapillary renal cell carcinoma

Identifiers

PMID32518984
OpenAlexW3034006418

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.